Progyny, Inc. Announces Fourth Quarter and Full Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Progyny (PGNY) Misses Q4 EPS by 1c, Revenues Miss; Offers Q1 & FY20 EPS/Revenue Outlook
March 5, 2020 4:16 PM ESTProgyny (NASDAQ: PGNY) reported Q4 EPS of $0.01, $0.01 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $65.12 million versus the consensus estimate of $66.07 million.
We had a strong fourth quarter, concluding a record year for Progyny, said David Schlanger, Chief Executive Officer of Progyny. In 2019, our selling season produced the greatest number of new clients and covered lives in our history, demonstrating that awareness of infertility as a medical condition is growing, and that employers are looking for leading benefits solutions that both provide the appropriate coverage and generate the best clinical... More
